5H-Dibenzo[b,e]azepin-6(11H)-one

We are 5H-Dibenzo[b,e]azepin-6(11H)-one CAS:1211-06-9 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:5H-Dibenzo[b,e]azepin-6(11H)-one
CAS.NO:1211-06-9
Synonyms:5H-Dibenzo[b,e]azepin-6(11H)-one
5,11-dihydrobenzo[c][1]benzazepin-6-one
5,6-dihydro-6-oxomorphanthridine
 
Physical and Chemical Properties:
Density 1.186g/cm3
Boiling Point 289.5ºC at 760mmHg
Molecular Formula C14H11NO
Molecular Weight 209.24300
Flash Point 169.8ºC
Vapour Pressure 0.0022mmHg at 25°C
Index of Refraction 1.619
 
Specification:
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Epinastine(CAS:80012-43-7)、Epinastine hydrobromide(CAS:127786-29-2) and Epinastine hydrochloride(CAS:108929-04-0).

5H-Dibenzo[b,e]azepin-6(11H)-one


Related News: Green Valley said it would launch the drug “very soon” in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug.2358-29-4 This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?2-bromo-4-chloropyridine CAS:22918-01-0 The overall competition in China’s specialty drug substance market is relatively moderate, but due to the higher technical barriers and higher entry barriers for new entrants, there will be no obvious intensified competition in the short term.1173807-85-6 The overall competition in China’s specialty drug substance market is relatively moderate, but due to the higher technical barriers and higher entry barriers for new entrants, there will be no obvious intensified competition in the short term.Remogliflozin is economical than other similar agents currently available in sodium glucose co-transporter-2 (SGLT2) inhibitors class, which shall help for its better access among middle and low socio-economic strata of the society, he added.

Related Products
Product Name
2-((4-(Carboxymethyl)phenoxy)methyl)benzoic acid View Details
5-Bromo-2-fluoropyridine View Details
Isovaleryl chloride View Details
3,5-Dimethyl-4-hydroxybenzonitrile manufacturer Polyquaternium-7 Cas:26590-05-6 manufacturer Triptorelin manufacturer 4-(trifluoromethyl)-1,3-dioxolan-2-one Cas:167951-80-6 manufacturer 1,4-difluorobenzene manufacturer